• Andrieu, J.-M., Djeridane, M. & Berthou, C. (2002) Very high risk Hodgkin's disease (HD): ABVD (4 cycles) plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles) (INT-CT) and RT. Interim results of the GOELAMS H97-GM multicentric randomized trial. Blood, 100, 811 (abstract).
  • Donnelly, G.B., Filippa, D., Moskowitz, C.H. & Portlock, C.S. (1999) Increased treatment failure in patients with CD20 positive classic Hodgkin's disease (HD). Blood, 94, 598 (abstract).
  • Federico, M., Bellei, M., Brice, P., Brugiatelli, M., BNagler, A., Gisselbrecht, C., Moretti, L., Colombat, P., Luminari, S., Fabbiano, F., Di Renzo, N., Goldstone, A., Carella, A.M., EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. (2003) High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. Journal Clinical Oncology, 21, 23202325.
  • Hall, P.A., D'Ardenne, A.J. & Stansfeld, A.G. (1988) Paraffin section immunohistochemistry.II. Hodgkin's disease and large cell anaplastic (Ki1) lymphoma. Histopathology, 13, 161169.
  • Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Modern Pathology, 13, 193207.
  • Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced stage Hodgkin's disease. New England Journal Medicine, 339, 15061514.
  • Kewalramani, T. & Moskowitz, C.H. (2001) Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits? Current Oncology Reports, 3, 271278.
  • Lester, E.P., Petroni, G.R., Barcos, M., Johnson, J.L., Millard, F.E., Cooper, M.R., Omura, G.A., Frei, E. III & Peterson, B.A. (2001) Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. Cancer Investigations, 19, 447458.
  • Polyak, M.J. & Deans, J.P. (2002) Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood, 99, 32563262.
  • Rassidakis, G.Z., Medeiros, L.J., Viviani, S., Bonfante, V., Nadali, G.P., Vassilakopoulos, T.P., Mesina, O., Herling, M., Angelopoulou, M.K., Giardini, R., Chilosi, M., Kittas, C., McLaughlin, P., Rodriguez, M.A., Romaguera, J., Bonadonna, G., Gianni, A.M., Pizzolo, G., Pangalis, G.A., Canbacillas, F. & Sarris, A.H. (2002) CD20 expression in Hodgkin and Reed–Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. Journal of Clinical Oncology, 20, 12781287.
  • Rehwald, U., Schulz, H., Reiser, M., Sieber, M., Staak, J.O., Morschhauser, F., Driessen, C., Rudiger, T., Muller-Hermelink, K., Diehl, V., Engert, A., German Hodgkin Lymphoma Study Group (GHSG). (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group, Blood, 101, 420424.
  • SAS/STAT Software (1997): Changes and Enhancements Through Release 6.12. Chapter 24. SAS Institute Inc., Cary, NC.
  • Schmid, C., Pan, L., Diss, T. & Isaacson, P.G. (1991) Expression of B-cell antigens by Hodgkin's and Reed–Sternberg cells. American Journal of Pathology, 4, 701707.
  • Straus, D.J., Gaynor, J.J., Myers, J., Merke, D.P., Caravelli, J., Chapman, D., Yahalom, J. & Clarkson, B.D. (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. Journal of Clinical Oncology, 8, 11731186.
  • Thomas, R.K., Re, D., Zander, T., Wolf, J. & Diehl, V. (2002) Epidemiology and etiology of Hodgkin's lymphoma. Annals of Oncology, 13, 147152.
  • Tzankov, A., Krugman, J., Fend, F., Fischhofer, M., Greil, R. & Dirnhofer, S. (2003) Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clinical Cancer Research, 9, 13811386.
  • von Wasielewski, R., Mengel, M., Fischer, R., Hansmann, M.L., Hubner, K., Franklin, J., Tesch, H., Paulus, U., Werner, M., Diehl, V. & Goergii, A. (1997) Classical Hodgkin's disease: clinical impact of the immunophenotype. American Journal of Pathology, 151, 11231130.